Hua Zhong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hua Zhong has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
Lan Xu
Department of Hematology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China
6 shared publicationsWanbin Fu
Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
5 shared publicationsJia Liu
Department of Hematology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China
4 shared publications- Bo Zhang
Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 shared publications - Zhiqiang Gao
Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital of Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 shared publications - Baohui Han
Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publications
Latest Publications
- Open Access
- 24 July 2026
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 25
Leveraging Immunotherapy in Acute Myeloid Leukemia Treatment: Opportunities and Challenges
Acute myeloid leukemia (AML) is a heterogeneous group of malignant clonal disorders originating from hematopoietic stem or progenitor cells. Despite significant advances in understanding its pathogenesis and the development of novel therapeutic agents, the overall prognosis for AML patients remains poor. Immunotherapies have demonstrated remarkable success in other hematologic malignancies and are increasingly being explored in AML. However, their clinical application remains challenging, owing to multiple factors such as limited target specificity, high disease heterogeneity, and the immunosuppressive bone marrow microenvironment (BMME). In this review, we provide a comprehensive overview of recent advances in four major immunotherapeutic strategies for AML: adoptive cell therapy, bispecific antibodies, immune checkpoint modulation, and cytokine-based therapies. We further discuss the key biological and clinical challenges that limit their efficacy, including antigen selection, tumor heterogeneity, and microenvironmental immune suppression, along with emerging strategies to overcome these obstacles. With continued progress in both basic and clinical research, immunotherapy holds great potential to achieve greater specificity, improved safety, and more durable responses, ultimately improving outcomes for patients with AML.
- 24 July 2026
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 25
Open AccessLeveraging Immunotherapy in Acute Myeloid Leukemia Treatment: Opportunities and Challenges
Acute myeloid leukemia (AML) is a heterogeneous group of malignant clonal disorders originating from hematopoietic stem or progenitor cells. Despite significant advances in understanding its pathogenesis and the development of novel therapeutic agents, the overall prognosis for AML patients remains poor. Immunotherapies have demonstrated remarkable success in other hematologic malignancies and are increasingly being explored in AML. However, their clinical application remains challenging, owing to multiple factors such as limited target specificity, high disease heterogeneity, and the immunosuppressive bone marrow microenvironment (BMME). In this review, we provide a comprehensive overview of recent advances in four major immunotherapeutic strategies for AML: adoptive cell therapy, bispecific antibodies, immune checkpoint modulation, and cytokine-based therapies. We further discuss the key biological and clinical challenges that limit their efficacy, including antigen selection, tumor heterogeneity, and microenvironmental immune suppression, along with emerging strategies to overcome these obstacles. With continued progress in both basic and clinical research, immunotherapy holds great potential to achieve greater specificity, improved safety, and more durable responses, ultimately improving outcomes for patients with AML.
- Open Access
- 11 June 2026
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 18
Efficacy and safety of first-line oral vinorelbine plus firmonertinib in refractory EGFR -mutated non-small cell lung cancer: study protocol of a multicenter, non-randomized, two-cohort study
Background: Although combinations of third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) with chemotherapy or amivantamab have significantly improved progression-free survival (PFS) and overall survival (OS) compared with EGFR-TKI monotherapy in EGFR -mutated advanced non-small cell lung cancer (NSCLC), the increased toxicities and requirement for intravenous administration of chemotherapy limit their practicality. Patients with EGFR -mutated advanced NSCLC who develop M1c2 disease or exhibit elevated programmed death-ligand 1 (PD-L1) expression represent a clinically refractory subgroup with a high unmet need for effective and convenient combination strategies. Objectives: This study is designed to evaluate the efficacy and safety of an all-oral regimen combining vinorelbine and firmonertinib (a third-generation EGFR-TKI) as first-line treatment in this refractory population. Design: This open-label, non-randomized, two-cohort study is conducted at two centers in China. Systematic treatment-naïve patients with histopathology confirmed EGFR -mutated (exon 19 deletion or exon 21 L858R mutation) NSCLC, who are not amenable to curative surgery or radiotherapy, will be recruited. Cohort 1 will comprise 54 metastatic NSCLC patients with M1c2 disease, and Cohort 2 will consist of 77 locally advanced or metastatic NSCLC patients with a PD-L1 tumor proportion score of ⩾25%. Recruitment began on December 11, 2025, and is currently in progress. Methods and analysis: During the one-cycle safety run-in period, six patients received oral vinorelbine (60 mg/m 2 on days 1 and 8) plus firmonertinib (80 mg once daily) as the starting dose. Dosing regimen for the subsequent expansion cohort will be determined based on the safety data from the safety run-in period. The treatment cycle is repeated every 3 weeks and will continue until disease progression or unacceptable toxicity. The primary endpoint is investigator-assessed PFS. Secondary endpoints are objective response rate, disease control rate, OS, and safety. Ethics: This study has received ethics approval from the ethical committee of the Shanghai Chest Hospital (approval number: IS25204). Discussion: To the best of our knowledge, this study represents the first evaluation of vinorelbine plus firmonertinib in EGFR -mutated locally advanced or metastatic NSCLC with M1c2 disease or elevated PD-L1 expression, aiming to provide an effective, tolerable, and convenient all-oral treatment option for this refractory population. Trial registration: The study protocol (version 1.2; July 18, 2025) was registered on October 24, 2025, at the Chinese Clinical Trial Registry (ChiCTR2500111096).
- 11 June 2026
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 18
Open AccessEfficacy and safety of first-line oral vinorelbine plus firmonertinib in refractory EGFR -mutated non-small cell lung cancer: study protocol of a multicenter, non-randomized, two-cohort study
Background: Although combinations of third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) with chemotherapy or amivantamab have significantly improved progression-free survival (PFS) and overall survival (OS) compared with EGFR-TKI monotherapy in EGFR -mutated advanced non-small cell lung cancer (NSCLC), the increased toxicities and requirement for intravenous administration of chemotherapy limit their practicality. Patients with EGFR -mutated advanced NSCLC who develop M1c2 disease or exhibit elevated programmed death-ligand 1 (PD-L1) expression represent a clinically refractory subgroup with a high unmet need for effective and convenient combination strategies. Objectives: This study is designed to evaluate the efficacy and safety of an all-oral regimen combining vinorelbine and firmonertinib (a third-generation EGFR-TKI) as first-line treatment in this refractory population. Design: This open-label, non-randomized, two-cohort study is conducted at two centers in China. Systematic treatment-naïve patients with histopathology confirmed EGFR -mutated (exon 19 deletion or exon 21 L858R mutation) NSCLC, who are not amenable to curative surgery or radiotherapy, will be recruited. Cohort 1 will comprise 54 metastatic NSCLC patients with M1c2 disease, and Cohort 2 will consist of 77 locally advanced or metastatic NSCLC patients with a PD-L1 tumor proportion score of ⩾25%. Recruitment began on December 11, 2025, and is currently in progress. Methods and analysis: During the one-cycle safety run-in period, six patients received oral vinorelbine (60 mg/m 2 on days 1 and 8) plus firmonertinib (80 mg once daily) as the starting dose. Dosing regimen for the subsequent expansion cohort will be determined based on the safety data from the safety run-in period. The treatment cycle is repeated every 3 weeks and will continue until disease progression or unacceptable toxicity. The primary endpoint is investigator-assessed PFS. Secondary endpoints are objective response rate, disease control rate, OS, and safety. Ethics: This study has received ethics approval from the ethical committee of the Shanghai Chest Hospital (approval number: IS25204). Discussion: To the best of our knowledge, this study represents the first evaluation of vinorelbine plus firmonertinib in EGFR -mutated locally advanced or metastatic NSCLC with M1c2 disease or elevated PD-L1 expression, aiming to provide an effective, tolerable, and convenient all-oral treatment option for this refractory population. Trial registration: The study protocol (version 1.2; July 18, 2025) was registered on October 24, 2025, at the Chinese Clinical Trial Registry (ChiCTR2500111096).
- Open Access
- 1 April 2026
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 15 (4) , 108
Narrative review of the similarities and differences between immune checkpoint inhibitor- and antibody-drug conjugate-associated pneumonitis
Review Article Narrative review of the similarities and differences between immune checkpoint inhibitor- and antibody-drug conjugate-associated pneumonitis Ruiting Tan, Fangfei Qian, Yao Zhang, Shuhui Cao, Hua Zhong
- 1 April 2026
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 15 (4) , 108
Open AccessNarrative review of the similarities and differences between immune checkpoint inhibitor- and antibody-drug conjugate-associated pneumonitis
Review Article Narrative review of the similarities and differences between immune checkpoint inhibitor- and antibody-drug conjugate-associated pneumonitis Ruiting Tan, Fangfei Qian, Yao Zhang, Shuhui Cao, Hua Zhong
- Open Access
Safety and efficacy of intrathecal pemetrexed and bevacizumab in non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): protocol for a single-arm, prospective, phase Ia trial
Introduction The prolonged survival of lung cancer patients is accompanied by an increasing incidence of leptomeningeal metastases (LM). Patients with LM have a poor prognosis, significantly impacting their quality of life and overall survival. Recent studies have shown that while intrathecal pemetrexed (IP) can improve symptoms and confer a survival benefit in non-small cell lung cancer (NSCLC) patients with LM, drug resistance remains a significant challenge. As for systemic therapy, intravenous bevacizumab combined with chemotherapy has demonstrated clinical benefits in NSCLC patients. However, clinical data on intrathecal bevacizumab remain scarce. Therefore, this study aims to preliminarily explore the efficacy and safety of intrathecal pemetrexed and bevacizumab in the treatment of NSCLC patients with LM. Methods and analysis This is a single-centre, single-arm, prospective, investigator-initiated phase Ia clinical trial sponsored by Shanghai Chest Hospital, involving patients with advanced NSCLC and LM. Participants will be enrolled and allocated into two predefined cohorts. Cohort A: six participants will receive IP monotherapy for safety exploration. Cohort B: participants will receive intrathecal pemetrexed and bevacizumab. Pemetrexed will be administered at a fixed dose, while the dosage exploration for bevacizumab will employ a combination of a 3+3 design and an accelerated titration design (ATD). The primary endpoint is the safety and the secondary endpoint is the overall survival (OS). Ethics and dissemination This study protocol (Version 1.1, dated 8 October 2024) was approved by the Ethics Commission of Shanghai Chest Hospital (IS24103) on 23 October 2024. Trial results will be published in a peer-reviewed journal. Trial registration number NCT06663306, ClinicalTrials.gov.
Open AccessSafety and efficacy of intrathecal pemetrexed and bevacizumab in non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): protocol for a single-arm, prospective, phase Ia trial
Introduction The prolonged survival of lung cancer patients is accompanied by an increasing incidence of leptomeningeal metastases (LM). Patients with LM have a poor prognosis, significantly impacting their quality of life and overall survival. Recent studies have shown that while intrathecal pemetrexed (IP) can improve symptoms and confer a survival benefit in non-small cell lung cancer (NSCLC) patients with LM, drug resistance remains a significant challenge. As for systemic therapy, intravenous bevacizumab combined with chemotherapy has demonstrated clinical benefits in NSCLC patients. However, clinical data on intrathecal bevacizumab remain scarce. Therefore, this study aims to preliminarily explore the efficacy and safety of intrathecal pemetrexed and bevacizumab in the treatment of NSCLC patients with LM. Methods and analysis This is a single-centre, single-arm, prospective, investigator-initiated phase Ia clinical trial sponsored by Shanghai Chest Hospital, involving patients with advanced NSCLC and LM. Participants will be enrolled and allocated into two predefined cohorts. Cohort A: six participants will receive IP monotherapy for safety exploration. Cohort B: participants will receive intrathecal pemetrexed and bevacizumab. Pemetrexed will be administered at a fixed dose, while the dosage exploration for bevacizumab will employ a combination of a 3+3 design and an accelerated titration design (ATD). The primary endpoint is the safety and the secondary endpoint is the overall survival (OS). Ethics and dissemination This study protocol (Version 1.1, dated 8 October 2024) was approved by the Ethics Commission of Shanghai Chest Hospital (IS24103) on 23 October 2024. Trial results will be published in a peer-reviewed journal. Trial registration number NCT06663306, ClinicalTrials.gov.
- 5 January 2025
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 25 (6) , 440-448
Prognostic Value of Dynamic Measurable Residual Disease Monitoring by Multiflowcytometry in Elderly Patients With Nonintensively Treated Acute Myeloid Leukemia
- 5 January 2025
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 25 (6) , 440-448
Prognostic Value of Dynamic Measurable Residual Disease Monitoring by Multiflowcytometry in Elderly Patients With Nonintensively Treated Acute Myeloid Leukemia
- Open Access
- 8 November 2024
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 13 (1) , e64950
Efficacy and Safety of a Therapy Combining Sintilimab and Chemotherapy With Cryoablation in the First-Line Treatment of Advanced Nonsquamous Non–Small Cell Lung Cancer: Protocol for a Phase II, Pilot, Single-Arm, Single-Center Study
Background: Immunotherapy has significantly advanced lung cancer treatment, particularly in nonsquamous non–small cell lung cancer (NSCLC), with overall response rates between 50% and 60%. However, about 30% of patients only achieve a stable disease state. Cryoablation has shown potential to enhance immunotherapy by modifying the tumor’s immune microenvironment through the release of antigens and immune factors. Addressing how to boost the immune response in these patients is critical. Objective: This study aims to investigate the efficacy and safety of immunochemotherapy in combination with cryoablation as a first-line treatment for advanced NSCLC. Methods: This is a phase II, pilot, open-label, single arm, single center, interventional study. Patients with stage IIIB to IIIC or IV NSCLC with T staging ranging from T1 to T2b will receive sintilimab (200 mg/m2 every 3 weeks) and chemotherapy. After 2 cycles, the feasibility of cryoablation will be considered for those with stable disease by a multidisciplinary team. Cryoablation with 3 freeze-thaw cycles will be performed for the main lesion. The third cycle of systemic therapy will begin 7 (SD 3) days after cryoablation. A total of 20 patients will be enrolled. Treatment will continue until the disease progresses, there is unacceptable toxicity, a participant withdraws consent, other discontinuation criteria are met, or the study reaches completion. The primary objective is to assess progression-free survival (PFS). The secondary objective is to assess efficacy through duration of response, disease control rate, overall survival (OS), and the safety profile. The exploratory objective is to investigate and compare immune factor changes after 2 cycles of immunochemotherapy and at 1, 3, and 7 days after cryoablation. Survival time will be estimated using the Kaplan-Meier method to calculate median PFS and OS. Any adverse events that occur during the trial will be promptly recorded. Results: The project was funded in 2024, and enrollment will be completed in 2025. The first results are expected to be submitted for publication in 2027. Conclusions: This study will provide evidence for the efficacy and safety of the combination of immunochemotherapy and cryoablation as a first-line treatment for advanced NSCLC. Although it has a limited sample size, the findings of this study will be used in the future to inform the design of a fully powered, 2-arm, larger-scale study. Trial Registration: ClinicalTrials.gov NCT06483009; https://clinicaltrials.gov/study/NCT06483009 International Registered Report Identifier (IRRID): PRR1-10.2196/64950
- 8 November 2024
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 13 (1) , e64950
Open AccessEfficacy and Safety of a Therapy Combining Sintilimab and Chemotherapy With Cryoablation in the First-Line Treatment of Advanced Nonsquamous Non–Small Cell Lung Cancer: Protocol for a Phase II, Pilot, Single-Arm, Single-Center Study
Background: Immunotherapy has significantly advanced lung cancer treatment, particularly in nonsquamous non–small cell lung cancer (NSCLC), with overall response rates between 50% and 60%. However, about 30% of patients only achieve a stable disease state. Cryoablation has shown potential to enhance immunotherapy by modifying the tumor’s immune microenvironment through the release of antigens and immune factors. Addressing how to boost the immune response in these patients is critical. Objective: This study aims to investigate the efficacy and safety of immunochemotherapy in combination with cryoablation as a first-line treatment for advanced NSCLC. Methods: This is a phase II, pilot, open-label, single arm, single center, interventional study. Patients with stage IIIB to IIIC or IV NSCLC with T staging ranging from T1 to T2b will receive sintilimab (200 mg/m2 every 3 weeks) and chemotherapy. After 2 cycles, the feasibility of cryoablation will be considered for those with stable disease by a multidisciplinary team. Cryoablation with 3 freeze-thaw cycles will be performed for the main lesion. The third cycle of systemic therapy will begin 7 (SD 3) days after cryoablation. A total of 20 patients will be enrolled. Treatment will continue until the disease progresses, there is unacceptable toxicity, a participant withdraws consent, other discontinuation criteria are met, or the study reaches completion. The primary objective is to assess progression-free survival (PFS). The secondary objective is to assess efficacy through duration of response, disease control rate, overall survival (OS), and the safety profile. The exploratory objective is to investigate and compare immune factor changes after 2 cycles of immunochemotherapy and at 1, 3, and 7 days after cryoablation. Survival time will be estimated using the Kaplan-Meier method to calculate median PFS and OS. Any adverse events that occur during the trial will be promptly recorded. Results: The project was funded in 2024, and enrollment will be completed in 2025. The first results are expected to be submitted for publication in 2027. Conclusions: This study will provide evidence for the efficacy and safety of the combination of immunochemotherapy and cryoablation as a first-line treatment for advanced NSCLC. Although it has a limited sample size, the findings of this study will be used in the future to inform the design of a fully powered, 2-arm, larger-scale study. Trial Registration: ClinicalTrials.gov NCT06483009; https://clinicaltrials.gov/study/NCT06483009 International Registered Report Identifier (IRRID): PRR1-10.2196/64950
- Open Access
- 31 July 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Efficacy and Safety of a Therapy Combining Sintilimab and Chemotherapy With Cryoablation in the First-Line Treatment of Advanced Nonsquamous Non–Small Cell Lung Cancer: Protocol for a Phase II, Pilot, Single-Arm, Single-Center Study (Preprint)
BACKGROUND Immunotherapy has significantly advanced lung cancer treatment, particularly in nonsquamous non–small cell lung cancer (NSCLC), with overall response rates between 50% and 60%. However, about 30% of patients only achieve a stable disease state. Cryoablation has shown potential to enhance immunotherapy by modifying the tumor’s immune microenvironment through the release of antigens and immune factors. Addressing how to boost the immune response in these patients is critical. OBJECTIVE This study aims to investigate the efficacy and safety of immunochemotherapy in combination with cryoablation as a first-line treatment for advanced NSCLC. METHODS This is a phase II, pilot, open-label, single arm, single center, interventional study. Patients with stage IIIB to IIIC or IV NSCLC with T staging ranging from T1 to T2b will receive sintilimab (200 mg/m2 every 3 weeks) and chemotherapy. After 2 cycles, the feasibility of cryoablation will be considered for those with stable disease by a multidisciplinary team. Cryoablation with 3 freeze-thaw cycles will be performed for the main lesion. The third cycle of systemic therapy will begin 7 (SD 3) days after cryoablation. A total of 20 patients will be enrolled. Treatment will continue until the disease progresses, there is unacceptable toxicity, a participant withdraws consent, other discontinuation criteria are met, or the study reaches completion. The primary objective is to assess progression-free survival (PFS). The secondary objective is to assess efficacy through duration of response, disease control rate, overall survival (OS), and the safety profile. The exploratory objective is to investigate and compare immune factor changes after 2 cycles of immunochemotherapy and at 1, 3, and 7 days after cryoablation. Survival time will be estimated using the Kaplan-Meier method to calculate median PFS and OS. Any adverse events that occur during the trial will be promptly recorded. RESULTS The project was funded in 2024, and enrollment will be completed in 2025. The first results are expected to be submitted for publication in 2027. CONCLUSIONS This study will provide evidence for the efficacy and safety of the combination of immunochemotherapy and cryoablation as a first-line treatment for advanced NSCLC. Although it has a limited sample size, the findings of this study will be used in the future to inform the design of a fully powered, 2-arm, larger-scale study. CLINICALTRIAL ClinicalTrials.gov NCT06483009; https://clinicaltrials.gov/study/NCT06483009 INTERNATIONAL REGISTERED REPORT PRR1-10.2196/64950
- 31 July 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessEfficacy and Safety of a Therapy Combining Sintilimab and Chemotherapy With Cryoablation in the First-Line Treatment of Advanced Nonsquamous Non–Small Cell Lung Cancer: Protocol for a Phase II, Pilot, Single-Arm, Single-Center Study (Preprint)
BACKGROUND Immunotherapy has significantly advanced lung cancer treatment, particularly in nonsquamous non–small cell lung cancer (NSCLC), with overall response rates between 50% and 60%. However, about 30% of patients only achieve a stable disease state. Cryoablation has shown potential to enhance immunotherapy by modifying the tumor’s immune microenvironment through the release of antigens and immune factors. Addressing how to boost the immune response in these patients is critical. OBJECTIVE This study aims to investigate the efficacy and safety of immunochemotherapy in combination with cryoablation as a first-line treatment for advanced NSCLC. METHODS This is a phase II, pilot, open-label, single arm, single center, interventional study. Patients with stage IIIB to IIIC or IV NSCLC with T staging ranging from T1 to T2b will receive sintilimab (200 mg/m2 every 3 weeks) and chemotherapy. After 2 cycles, the feasibility of cryoablation will be considered for those with stable disease by a multidisciplinary team. Cryoablation with 3 freeze-thaw cycles will be performed for the main lesion. The third cycle of systemic therapy will begin 7 (SD 3) days after cryoablation. A total of 20 patients will be enrolled. Treatment will continue until the disease progresses, there is unacceptable toxicity, a participant withdraws consent, other discontinuation criteria are met, or the study reaches completion. The primary objective is to assess progression-free survival (PFS). The secondary objective is to assess efficacy through duration of response, disease control rate, overall survival (OS), and the safety profile. The exploratory objective is to investigate and compare immune factor changes after 2 cycles of immunochemotherapy and at 1, 3, and 7 days after cryoablation. Survival time will be estimated using the Kaplan-Meier method to calculate median PFS and OS. Any adverse events that occur during the trial will be promptly recorded. RESULTS The project was funded in 2024, and enrollment will be completed in 2025. The first results are expected to be submitted for publication in 2027. CONCLUSIONS This study will provide evidence for the efficacy and safety of the combination of immunochemotherapy and cryoablation as a first-line treatment for advanced NSCLC. Although it has a limited sample size, the findings of this study will be used in the future to inform the design of a fully powered, 2-arm, larger-scale study. CLINICALTRIAL ClinicalTrials.gov NCT06483009; https://clinicaltrials.gov/study/NCT06483009 INTERNATIONAL REGISTERED REPORT PRR1-10.2196/64950
- 30 March 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 132, 111927
Single-cell sequencing unveils T-cell characteristic in acute myeloid leukemia
- 30 March 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 132, 111927
Single-cell sequencing unveils T-cell characteristic in acute myeloid leukemia
- 11 February 2024
- Published by Wiley in European Journal of Haematology
- Vol. 112 (6) , 870-878
Minimal residual disease monitoring in acute myeloid leukemia: Focus on MFC‐MRD and treatment guidance for elderly patients
Acute myeloid leukemia (AML) is distinguished by clonal growth of myeloid precursor cells, which impairs normal hematopoiesis. Minimal residual disease (MRD) refers to the residual leukemia cells that persist after chemotherapy. Patients who test positive for MRD have a higher likelihood of experiencing a recurrence, regardless of the specific chemotherapy approach used. Multi‐parameter flow cytometry (MFC), polymerase chain reaction (PCR), and next‐generation sequencing (NGS) are commonly employed techniques for identifying MRD. In the context of AML, patients are frequently monitored for measurable residual disease via multi‐parameter flow cytometry (MFC‐MRD). In order to explore recent advancements in AML and MRD diagnosis, an extensive search of the PubMed database was conducted, focusing on relevant research in the past 20 years. This review aims to examine various MRD monitoring methods, the optimal time points for assessment, as well as different specimen types used. Additionally, it underscores the significance of MFC‐MRD assessment in guiding the treatment of elderly AML.
- 11 February 2024
- Published by Wiley in European Journal of Haematology
- Vol. 112 (6) , 870-878
Minimal residual disease monitoring in acute myeloid leukemia: Focus on MFC‐MRD and treatment guidance for elderly patients
Acute myeloid leukemia (AML) is distinguished by clonal growth of myeloid precursor cells, which impairs normal hematopoiesis. Minimal residual disease (MRD) refers to the residual leukemia cells that persist after chemotherapy. Patients who test positive for MRD have a higher likelihood of experiencing a recurrence, regardless of the specific chemotherapy approach used. Multi‐parameter flow cytometry (MFC), polymerase chain reaction (PCR), and next‐generation sequencing (NGS) are commonly employed techniques for identifying MRD. In the context of AML, patients are frequently monitored for measurable residual disease via multi‐parameter flow cytometry (MFC‐MRD). In order to explore recent advancements in AML and MRD diagnosis, an extensive search of the PubMed database was conducted, focusing on relevant research in the past 20 years. This review aims to examine various MRD monitoring methods, the optimal time points for assessment, as well as different specimen types used. Additionally, it underscores the significance of MFC‐MRD assessment in guiding the treatment of elderly AML.
- Open Access
- 19 May 2022
- Published by Springer Nature in Cancer Cell International
- Vol. 22 (1) , 1-10
G-CSF upregulates the expression of aquaporin-9 through CEBPB to enhance the cytotoxic activity of arsenic trioxide to acute myeloid leukemia cells
Arsenic trioxide (ATO) is highly effective in acute promyelocytic leukemia (APL) patients, but it fails to show satisfactory efficacy in other acute myeloid leukemia (AML) patients with non-APL subtypes. Different from the APL cells, most non-APL AML cells express low levels of the ATO transporter Aquaporin-9 (AQP9) protein, making them less sensitive to ATO treatment. Recently, we found that granulocyte colony stimulating factor (G-CSF) can upregulate the expression of AQP9. We hypothesized that the pretreatment with G-CSF may enhance the antitumor effect of ATO in non-APL AML cells. In addition, we aimed to elucidate the underlying mechanisms by which G-CSF upregulates the expression of AQP9. Non-APL AML cell lines including THP-1 and HL-60 were pretreated with or without G-CSF (100 ng/ml) for 24 h, followed by the treatment with ATO (2 μM) for 48 h. Cell morphology was observed under the microscope after Wright-Giemsa staining. Flow cytometry was performed to evaluate the cell apoptosis levels. The intracellular concentrations of ATO were determined by atomic fluorescence spectrometry. The mRNA and protein expression were respectively measured by quantitative reverse transcription PCR (RT-qPCR) and western blotting. Target genes were knocked down by transfection with small interfering RNA (siRNA), or overexpressed by transfection with overexpression plasmids. The cell line derived xenograft mouse model was established to confirm the results of the in vitro experiments. Compared with using ATO alone, the combination of G-CSF with ATO induced the cell apoptosis more dramatically. G-CSF upregulated the expression of AQP9 and enhanced the intracellular concentrations of ATO in AML cells. When AQP9 was overexpressed, it markedly enhanced the cytotoxic activity of ATO. On the other hand, when AQP9 was knocked down, it profoundly attenuated the combinational effect. Moreover, we found that the upregulation of AQP9 by G-CSF depends on the transcription factor CCAAT enhancer binding protein beta (CEBPB). We also demonstrated that the combination of G-CSF and ATO significantly inhibited tumor growth in the xenograft mouse model. The combination of G-CSF and ATO may be a potential therapeutic strategy for AML patients.
- 19 May 2022
- Published by Springer Nature in Cancer Cell International
- Vol. 22 (1) , 1-10
Open AccessG-CSF upregulates the expression of aquaporin-9 through CEBPB to enhance the cytotoxic activity of arsenic trioxide to acute myeloid leukemia cells
Arsenic trioxide (ATO) is highly effective in acute promyelocytic leukemia (APL) patients, but it fails to show satisfactory efficacy in other acute myeloid leukemia (AML) patients with non-APL subtypes. Different from the APL cells, most non-APL AML cells express low levels of the ATO transporter Aquaporin-9 (AQP9) protein, making them less sensitive to ATO treatment. Recently, we found that granulocyte colony stimulating factor (G-CSF) can upregulate the expression of AQP9. We hypothesized that the pretreatment with G-CSF may enhance the antitumor effect of ATO in non-APL AML cells. In addition, we aimed to elucidate the underlying mechanisms by which G-CSF upregulates the expression of AQP9. Non-APL AML cell lines including THP-1 and HL-60 were pretreated with or without G-CSF (100 ng/ml) for 24 h, followed by the treatment with ATO (2 μM) for 48 h. Cell morphology was observed under the microscope after Wright-Giemsa staining. Flow cytometry was performed to evaluate the cell apoptosis levels. The intracellular concentrations of ATO were determined by atomic fluorescence spectrometry. The mRNA and protein expression were respectively measured by quantitative reverse transcription PCR (RT-qPCR) and western blotting. Target genes were knocked down by transfection with small interfering RNA (siRNA), or overexpressed by transfection with overexpression plasmids. The cell line derived xenograft mouse model was established to confirm the results of the in vitro experiments. Compared with using ATO alone, the combination of G-CSF with ATO induced the cell apoptosis more dramatically. G-CSF upregulated the expression of AQP9 and enhanced the intracellular concentrations of ATO in AML cells. When AQP9 was overexpressed, it markedly enhanced the cytotoxic activity of ATO. On the other hand, when AQP9 was knocked down, it profoundly attenuated the combinational effect. Moreover, we found that the upregulation of AQP9 by G-CSF depends on the transcription factor CCAAT enhancer binding protein beta (CEBPB). We also demonstrated that the combination of G-CSF and ATO significantly inhibited tumor growth in the xenograft mouse model. The combination of G-CSF and ATO may be a potential therapeutic strategy for AML patients.